Navigation Links
VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291
Date:12/3/2009

SAN FRANCISCO, Dec. 3 /PRNewswire-FirstCall/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced that it has completed the last patient visit in its Phase 2 FDG-PET clinical trial of VIA-2291.

The FDG-PET trial enrolled 52 patients and was carried out at five sites in the US and Canada including Massachusetts General Hospital, Mount Sinai School of Medicine, University of Massachusetts, Winthrop University Hospital and Montreal Heart Institute. The study is designed to measure the impact of VIA-2291 on reducing inflammation in carotid plaque in treated patients. Patients were enrolled following an acute coronary syndrome event, such as heart attack or stroke, into the 24 week, randomized, double blind, placebo-controlled study. Endpoints in the study include reduction in atherosclerotic plaque inflammation as measured by serial FDG-PET scans. Completion of the data analysis and presentation of clinical trial results are anticipated in early 2010.

About VIA Pharmaceuticals, Inc.

VIA Pharmaceuticals, Inc. is a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease. VIA's lead candidate, VIA-2291, targets a significant unmet medical need by reducing inflammation in plaque, which is an underlying cause of atherosclerosis and its complications, including heart attack and stroke. In addition, VIA's pipeline of drug candidates includes other compounds to address other underlying causes of cardiovascular disease: high cholesterol, diabetes and inflammation. For more information, visit: http://www.viapharmaceuticals.com.

Forward Looki
'/>"/>

SOURCE VIA Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... 01, 2014 TeselaGen Biotechnology ... Foundation to expand their bioCAD/CAM software suite, which uses ... DNA. The Small Business Innovation Research Phase II grant ... under exclusive license from the Lawrence Berkeley National Laboratory. ... , an LBNL laboratory that develops alternative fuel technologies ...
(Date:9/30/2014)... September 30, 2014 Applying a well-known optical ... at Harvard University has demonstrated the ability to ... work that holds promise for making future, flexible ... the sides of next-gen rocket ships and spacecraft ... passes through oil in water, it becomes iridescent, ...
(Date:9/30/2014)... Shimadzu Scientific Instruments has released ... highly precise tool for measuring displacement in rubber ... 1000-mm maximum movement distance, the DSES-1000 can measure ... length of 10 mm. In addition, it achieves ... stroke and within +/- 100 µm below 50-mm ...
(Date:9/30/2014)... Sept. 30, 2014  RegeneRx Biopharmaceuticals, Inc. (OTC: ... it has received a Canadian Patent for Inhibition ... This patent includes claims using thymosin beta 4, ... peptides for these purposes.  The patent will expire ... Inc. ( www.regenerx.com ) RegeneRx ...
Breaking Biology Technology:TeselaGen Receives $750k NSF SBIR Phase II Award 2TeselaGen Receives $750k NSF SBIR Phase II Award 3Taking thin films to the extreme 2Shimadzu’s New Long-Travel Extensometer Increases Precision for Soft Material Testing 2RegeneRx Receives Canadian Patent for Inhibition or Reversal of Skin Aging 2
... Six new stem cell therapies, all forecast to reach physicians ... Summit on February 16 in New York City. These new therapies ... at least one FDA-approved stem cell drug. New studies showing rehydration ... are also on the agenda. , The Stem Cell Summit is ...
... REHOVOT, Israel, December 31 D-Pharm Ltd ... its,Phase III clinical study of DP-b99 (MACSI). The first patient ... trial involves,numerous medical centers in the US, Canada, Europe, Israel, ... product developed,for protection of brain cells suffering from restricted blood ...
... ... For The Massachusetts Biotechnology Council , ... Boston, MA (PRWEB) December 31, 2009 -- Social Media ... Biotechnology Council’s (MassBio) has selected the Boston-based Social Media Marketing Agency to plan and ...
Cached Biology Technology:5th Annual Summit to Feature New Stem Cell Therapies 2D-Pharm (TASE: DPRM) Announces Enrollment of First Patient in DP-b99 Phase III Efficacy Study, MACSI 2D-Pharm (TASE: DPRM) Announces Enrollment of First Patient in DP-b99 Phase III Efficacy Study, MACSI 3 The Massachusetts Biotechnology Council Selects Social Media Marketing Agency 451 Marketing To Develop A Social Media Strategy For 2010 2 The Massachusetts Biotechnology Council Selects Social Media Marketing Agency 451 Marketing To Develop A Social Media Strategy For 2010 3
(Date:9/30/2014)... the Mediterranean each year, but its deep-blue waters ... Almost 1,000 alien species, including fish, crustaceans, and ... human activities. In the open-access journal Frontiers ... researchers analyzed data from a new information system ... the introduction of alien species has changed the ...
(Date:9/30/2014)... --- Do we think of nature as something that we ... need to "preserve?" Or do we think of ourselves as ... of nature, but what about a house? , The ... also reflected in our actions, our speech and in cultural ... the University of Washington, the American Indian Center of Chicago ...
(Date:9/30/2014)... 2014--Sea monkeys have captured the popular attention of both ... life cycle -- sold as dehydrated eggs, these tiny ... more than a tank of salt water. , ... other zooplankton, brine shrimp vertically migrate in large groups ... the surface at night and retreating deeper during the ...
Breaking Biology News(10 mins):Biodiversity in the Mediterranean is threatened by alien species 2The cultural side of science communication 2Laser-guided sea monkeys show how zooplankton migrations may affect global ocean currents 2
... After a decade and a half of near stagnation, ... chronic illness instead of a terminal disease, a leading Colorado ... drugs have different and innovative methods of action. One is ... another is radiotherapy; and the final one is the first ...
... ingredient in the food industry because of its association with ... the February issue of the Journal of Food Science ... fish oil can be added to goat cheese to deliver ... or shelf-life. Fish oil delivers higher levels and more ...
... Republic of Congo has formally expanded Nouabal-Ndoki National Park ... most pristine forests and a population of "nave" chimpanzees ... apes investigate the conservationists who study them rather than ... 100-plus square-mile dense swamp forest and its unique great ...
Cached Biology News:4 new drugs will change prostate cancer care 2Great news for chimpanzees 2Great news for chimpanzees 3
... Signal Enhancer does for enzyme-/substrate-based blotting what intensifying ... the signal up to 10-fold (or one order ... Western Blot Signal Enhancer membrane treatment is a ... to your current Western blotting protocol. The result ...
...
... revolutionary new application for DNA and ... interface, Expression makes complex computational analyses ... uses the very latest computing technology ... way sequences are analysed. Features include: ...
... Partek Genomics Solution is a ... interactive data visualization specifically designed to ... Designed for high-dimensional genomic studies containing ... is fast, memory efficient and will ...
Biology Products: